These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 19022245)

  • 1. ErbB receptors and cell polarity: new pathways and paradigms for understanding cell migration and invasion.
    Feigin ME; Muthuswamy SK
    Exp Cell Res; 2009 Feb; 315(4):707-16. PubMed ID: 19022245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ErbB receptors and their role in cancer progression.
    Holbro T; Civenni G; Hynes NE
    Exp Cell Res; 2003 Mar; 284(1):99-110. PubMed ID: 12648469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ErbB2 is necessary for induction of carcinoma cell invasion by ErbB family receptor tyrosine kinases.
    Spencer KS; Graus-Porta D; Leng J; Hynes NE; Klemke RL
    J Cell Biol; 2000 Jan; 148(2):385-97. PubMed ID: 10648571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of ErbB receptor negative regulation and relevance in cancer.
    Fry WH; Kotelawala L; Sweeney C; Carraway KL
    Exp Cell Res; 2009 Feb; 315(4):697-706. PubMed ID: 18706412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Luteinizing hormone-induced up-regulation of ErbB-2 is insufficient stimulant of growth and invasion in ovarian cancer cells.
    Warrenfeltz SW; Lott SA; Palmer TM; Gray JC; Puett D
    Mol Cancer Res; 2008 Nov; 6(11):1775-85. PubMed ID: 19010824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heregulin inhibits proliferation via ERKs and phosphatidyl-inositol 3-kinase activation but regulates urokinase plasminogen activator independently of these pathways in metastatic mammary tumor cells.
    Puricelli L; Proietti CJ; Labriola L; Salatino M; Balañá ME; Aguirre Ghiso J; Lupu R; Pignataro OP; Charreau EH; Bal de Kier Joffé E; Elizalde PV
    Int J Cancer; 2002 Aug; 100(6):642-53. PubMed ID: 12209601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Signaling through ShcA is required for transforming growth factor beta- and Neu/ErbB-2-induced breast cancer cell motility and invasion.
    Northey JJ; Chmielecki J; Ngan E; Russo C; Annis MG; Muller WJ; Siegel PM
    Mol Cell Biol; 2008 May; 28(10):3162-76. PubMed ID: 18332126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion.
    Fichter CD; Przypadlo CM; Buck A; Herbener N; Riedel B; Schäfer L; Nakagawa H; Walch A; Reinheckel T; Werner M; Lassmann S
    J Pathol; 2017 Dec; 243(4):481-495. PubMed ID: 28940194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Focal adhesion kinase-related proline-rich tyrosine kinase 2 and focal adhesion kinase are co-overexpressed in early-stage and invasive ErbB-2-positive breast cancer and cooperate for breast cancer cell tumorigenesis and invasiveness.
    Behmoaram E; Bijian K; Jie S; Xu Y; Darnel A; Bismar TA; Alaoui-Jamali MA
    Am J Pathol; 2008 Nov; 173(5):1540-50. PubMed ID: 18832579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controlled activation of ErbB1/ErbB2 heterodimers promote invasion of three-dimensional organized epithelia in an ErbB1-dependent manner: implications for progression of ErbB2-overexpressing tumors.
    Zhan L; Xiang B; Muthuswamy SK
    Cancer Res; 2006 May; 66(10):5201-8. PubMed ID: 16707444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ErbB receptors and signaling pathways in cancer.
    Hynes NE; MacDonald G
    Curr Opin Cell Biol; 2009 Apr; 21(2):177-84. PubMed ID: 19208461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions.
    Alroy I; Yarden Y
    FEBS Lett; 1997 Jun; 410(1):83-6. PubMed ID: 9247128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ErbB receptor negative regulatory mechanisms: implications in cancer.
    Sweeney C; Miller JK; Shattuck DL; Carraway KL
    J Mammary Gland Biol Neoplasia; 2006 Jan; 11(1):89-99. PubMed ID: 16865534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Control of ErbB signaling through metalloprotease mediated ectodomain shedding of EGF-like factors.
    Sanderson MP; Dempsey PJ; Dunbar AJ
    Growth Factors; 2006 Jun; 24(2):121-36. PubMed ID: 16801132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zinc finger transcription factors designed for bispecific coregulation of ErbB2 and ErbB3 receptors: insights into ErbB receptor biology.
    Lund CV; Popkov M; Magnenat L; Barbas CF
    Mol Cell Biol; 2005 Oct; 25(20):9082-91. PubMed ID: 16199884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Signal transduction and oncogenesis by ErbB/HER receptors.
    Marmor MD; Skaria KB; Yarden Y
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):903-13. PubMed ID: 14967450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis.
    Guo W; Pylayeva Y; Pepe A; Yoshioka T; Muller WJ; Inghirami G; Giancotti FG
    Cell; 2006 Aug; 126(3):489-502. PubMed ID: 16901783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of cancer cell migration by epidermal growth factor is initiated by specific phosphorylation of tyrosine 1248 of c-erbB-2 receptor via EGFR.
    Dittmar T; Husemann A; Schewe Y; Nofer JR; Niggemann B; Zänker KS; Brandt BH
    FASEB J; 2002 Nov; 16(13):1823-5. PubMed ID: 12354693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flotillin depletion affects ErbB protein levels in different human breast cancer cells.
    Asp N; Pust S; Sandvig K
    Biochim Biophys Acta; 2014 Sep; 1843(9):1987-96. PubMed ID: 24747692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receptor tyrosine kinase signalling as a target for cancer intervention strategies.
    Zwick E; Bange J; Ullrich A
    Endocr Relat Cancer; 2001 Sep; 8(3):161-73. PubMed ID: 11566607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.